669 related articles for article (PubMed ID: 20522841)
1. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD.
Dahl R; Chung KF; Buhl R; Magnussen H; Nonikov V; Jack D; Bleasdale P; Owen R; Higgins M; Kramer B;
Thorax; 2010 Jun; 65(6):473-9. PubMed ID: 20522841
[TBL] [Abstract][Full Text] [Related]
2. Effects of long-acting bronchodilators in COPD patients according to COPD severity and ICS use.
Decramer M; Dahl R; Kornmann O; Korn S; Lawrence D; McBryan D
Respir Med; 2013 Feb; 107(2):223-32. PubMed ID: 23219347
[TBL] [Abstract][Full Text] [Related]
3. Bronchodilator effects of indacaterol and formoterol in patients with COPD.
Beier J; Beeh KM; Brookman L; Peachey G; Hmissi A; Pascoe S
Pulm Pharmacol Ther; 2009 Dec; 22(6):492-6. PubMed ID: 19465142
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-daily QVA149 compared with the free combination of once-daily tiotropium plus twice-daily formoterol in patients with moderate-to-severe COPD (QUANTIFY): a randomised, non-inferiority study.
Buhl R; Gessner C; Schuermann W; Foerster K; Sieder C; Hiltl S; Korn S
Thorax; 2015 Apr; 70(4):311-9. PubMed ID: 25677679
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of indacaterol 75 μg once daily in patients aged ≥40 years with chronic obstructive pulmonary disease: results from 2 double-blind, placebo-controlled 12-week studies.
Kerwin EM; Gotfried MH; Lawrence D; Lassen C; Kramer B
Clin Ther; 2011 Dec; 33(12):1974-84. PubMed ID: 22177371
[TBL] [Abstract][Full Text] [Related]
6. 24-hour bronchodilator efficacy of single doses of indacaterol in subjects with COPD: comparison with placebo and formoterol.
Bauwens O; Ninane V; Van de Maele B; Firth R; Dong F; Owen R; Higgins M
Curr Med Res Opin; 2009 Feb; 25(2):463-70. PubMed ID: 19192991
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
8. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium.
Donohue JF; Fogarty C; Lötvall J; Mahler DA; Worth H; Yorgancioglu A; Iqbal A; Swales J; Owen R; Higgins M; Kramer B;
Am J Respir Crit Care Med; 2010 Jul; 182(2):155-62. PubMed ID: 20463178
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of indacaterol 150 and 300 µg in chronic obstructive pulmonary disease patients from six Asian areas including Japan: a 12-week, placebo-controlled study.
Kinoshita M; Lee SH; Hang LW; Ichinose M; Hosoe M; Okino N; Prasad N; Kramer B; Fukuchi Y;
Respirology; 2012 Feb; 17(2):379-89. PubMed ID: 22122202
[TBL] [Abstract][Full Text] [Related]
10. Profiling the bronchodilator effects of the novel ultra-long-acting β2-agonist indacaterol against established treatments in chronic obstructive pulmonary disease.
Vogelmeier C; Magnussen H; LaForce C; Owen R; Kramer B
Ther Adv Respir Dis; 2011 Oct; 5(5):345-57. PubMed ID: 21719531
[TBL] [Abstract][Full Text] [Related]
11. Profiling the effects of indacaterol on dyspnoea and health status in patients with COPD.
Jones PW; Mahler DA; Gale R; Owen R; Kramer B
Respir Med; 2011 Jun; 105(6):892-9. PubMed ID: 21397482
[TBL] [Abstract][Full Text] [Related]
12. [Indacaterol--a new hope for maximising bronchodilation?].
Mihălţan F
Pneumologia; 2011; 60(1):21-5. PubMed ID: 21548196
[TBL] [Abstract][Full Text] [Related]
13. Chronic treatment with indacaterol and airway response to salbutamol in stable COPD.
Cazzola M; Rogliani P; Ruggeri P; Segreti A; Proietto A; Picciolo S; Matera MG
Respir Med; 2013 Jun; 107(6):848-53. PubMed ID: 23490225
[TBL] [Abstract][Full Text] [Related]
14. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison.
Kornmann O; Dahl R; Centanni S; Dogra A; Owen R; Lassen C; Kramer B;
Eur Respir J; 2011 Feb; 37(2):273-9. PubMed ID: 20693243
[TBL] [Abstract][Full Text] [Related]
15. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
16. Indacaterol 75 μg once daily for the treatment of patients with chronic obstructive pulmonary disease: a North American perspective.
Kerwin EM; Williams J
Ther Adv Respir Dis; 2013 Feb; 7(1):25-37. PubMed ID: 23296242
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of indacaterol 75 μg once-daily on dyspnea and health status: results of two double-blind, placebo-controlled 12-week studies.
Gotfried MH; Kerwin EM; Lawrence D; Lassen C; Kramer B
COPD; 2012 Dec; 9(6):629-36. PubMed ID: 23020650
[TBL] [Abstract][Full Text] [Related]
18. The impact of treatment with indacaterol in patients with COPD: A post-hoc analysis according to GOLD 2011 categories A to D.
Kerstjens HA; Deslée G; Dahl R; Donohue JF; Young D; Lawrence D; Kornmann O
Pulm Pharmacol Ther; 2015 Jun; 32():101-8. PubMed ID: 25743376
[TBL] [Abstract][Full Text] [Related]
19. Integrating indacaterol dose selection in a clinical study in COPD using an adaptive seamless design.
Barnes PJ; Pocock SJ; Magnussen H; Iqbal A; Kramer B; Higgins M; Lawrence D
Pulm Pharmacol Ther; 2010 Jun; 23(3):165-71. PubMed ID: 20080201
[TBL] [Abstract][Full Text] [Related]
20. Nebulized arformoterol in patients with COPD: a 12-week, multicenter, randomized, double-blind, double-dummy, placebo- and active-controlled trial.
Baumgartner RA; Hanania NA; Calhoun WJ; Sahn SA; Sciarappa K; Hanrahan JP
Clin Ther; 2007 Feb; 29(2):261-78. PubMed ID: 17472819
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
